Biotek-snakken — Februar 2021
-
-
@Sukkeralf Mange tak for din vurdering. Biotek kan jo tage tid, så jeg vil holde fast og væbne mig med lidt mere tålmodighed
. -
Jeg synes Curasight ser rigtigt spændende ud og overvejer at købe lidt ind i den. De får publiceret en artikel i næste uge med data fra deres fase 2 studie der måske kan være en driver for kursen
, men er der nogen af jer der har kigget aktien og produktet efter i sømmene? -
-
For followers of this space there is one other asset to watch: Lilly’s LY3434172. This is an anti-PD-1 x PD-L1 bispecific antibody, and has been in a phase I study for over a year, but no clinical data seem to have been presented yet.
A preclinical paper published this month in Cancer Immunology Research suggested that LY3434172 had demonstrated its “enhanced immunomodulatory properties”. Human data with LY3434172, and an update on Beigene’s combo strategy, are keenly awaited.
-
@Sukkeralf: Jeg tjekkede Eli Lillys Q4 investor presentation den anden dag, men LY3434172 var stadig ikke angivet i deres pipeline:(
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind